Abstract C2: Selection for combinational studies through biomarker stratification in colorectal patient-derived explant models.
Denis Alférez(AstraZeneca (United Kingdom)), Robert W. Wilkinson(Immunocore (United Kingdom)), Sarah V. Holt(Pharma Nord (United Kingdom)), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Gael McWalter(AstraZeneca (United Kingdom)), Stephen R. Wedge(Newcastle University), Mitch Revill(AstraZeneca (United Kingdom)), Jonathan R. Dry(AstraZeneca (United Kingdom)), Garry Beran(AstraZeneca (United Kingdom)), P. Hedge(AstraZeneca (United Kingdom)), Susie Weston(AstraZeneca (United Kingdom)), Paul D. Smith(Epworth Hospital)
Cited by 0
Related Papers
AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer
|Cancer Research|2005|710
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Clinical development of new drug–radiotherapy combinations
|Nature Reviews Clinical Oncology|2016|317